Professor Clive Morris
Chief Medical Officer

Clive joined the leadership team in May 2016 and leads the clinical development strategy.  Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ. He has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. Most recently Clive founded and lead Health Innovation Manchester, to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services. He is also a non-executive director of Wheatsheaf investments and the InnovateUK Medicines Discovery Catapult. Clive is accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, has an Executive MBA and Honorary Professorship of Translational Medicine at the University of Manchester, and trained as a physician at the University of Manchester.

Jamie Platt PhD
Chief Operations Officer

Jamie leads the global clinical laboratory operations at Inivata. She was engaged as a consultant in March 2017 and joined the team on a full-time basis in Sept 2017. She has extensive expertise in sequencing and molecular systematics, including population genetics. During her 15 years in clinical diagnostics, Jamie has developed and validated numerous high complexity sequencing assays in the clinical areas of Oncology, Infectious Disease and Molecular Genetics and has introduced custom, industrial-grade automation to high complexity, sequencing assays. She has spent more than 10 years overseeing development and validation of Next Generation Sequencing Assays for both clinical diagnostics and clinical trials and has special interest in applying advanced sequencing technologies (NGS) to improve personalized healthcare. Jamie received her PhD in Molecular and Cellular Biology from Oregon State University and completed postdoctoral training in population genetics at the University of California, Berkeley.

Nitzan Rosenfeld PhD
Chief Scientific Officer

Nitzan is one of the founders of Inivata and Chief Scientific Officer. Nitzan is a world-leader in circulating tumor DNA biology and joined Cancer Research UK’s Cambridge Research Institute, now part of the University of Cambridge in 2009, where he combines new molecular and genomics approaches to develop new diagnostics. Previously he was head of Computational Biology at Rosetta Genomics and led development of molecular diagnostic tests. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and a prestigious ERC Starting Grant.  In 2015, Nitzan received the Foulkes Medal which is awarded biennially to an outstanding bioscience researcher within ten years of completing their PhD. He originally trained in Physics, and specialized in quantitative molecular biology, obtaining a PhD in Systems Biology from the Weizman Institute of Science, Israel.

Tim Shannon
Chief Financial Officer

Tim joined Inivata in 2016 and leads the finance team. Prior to joining Inivata he formulated and implemented financial controls and process improvements supporting business growth and expansion most recently at Baxano Surgical and Talecris Biotherapeutics. His background in technology, life sciences, and distribution environments is particularly relevant as Inivata moves forward towards commercialization. While at Talecris, Tim managed the Initial Public Offering (IPO) at a $3.28 billion valuation and has managed merger and acquisition transactions. Tim also has operational business experience across critical issues including budgeting, investor relations, systems implementation, and risk management. Tim has a Bachelor of Science in Business Administration from Appalachian State University and is a CPA, having spent the first 15 years of his career with PwC.

John Beeler PhD
VP, Portfolio Strategy and Life Cycle Management

John oversees portfolio strategy and life cycle management ensuring that product improvements and new product development are at the heart of the company’s mission. John has over 20 years of product and business development experience spanning the pharmaceutical and diagnostic industry including a history of having established and managed partnerships with leading pharmaceutical companies. Most recently he served as Director, Theranostics and Business Development at bioMerieux where he was responsible for executing companion diagnostic development and commercialization agreements with GlaxoSmithKline, Novartis and Gilead. John has published and presented at several scientific meetings and symposia on the topic of developing companion diagnostics and implementing personalized medicine initiatives. He holds a Masters degree in biology from Villanova University and a PhD in pharmacology from the University of South Carolina School of Medicine.

Patrice Love
Director of People and Organisation Development

Patrice has led HR activities since the early formation of the company in 2014. She has experience in early stage start-ups and pre-IPO companies, particularly in the life science and technology sectors, both in Europe and USA. Patrice’s career started in BT and in the latter years, with BT Brightstar, BT’s first corporate incubator as Head of Operations. She was also a Director at British manufacturer, Timberwolf and before joining Inivata, she owned her own consultancy business, supporting start-ups with a range of services including Operations, HR, Marketing and Finance. During her consultancy, she moved to New York for a year where she set up a US business for a UK technology company. Patrice is a Board Member of the Suffolk Chamber of Commerce, Suffolk Business Women, and an Ambassador for Suffolk Inward Investment and until recently, a Trust Governor at Suffolk One college.

Vincent Plagnol PhD
VP, Computational Biology

Vincent leads the Inivata computational biology team. Vincent was educated in Paris, France, where he obtained his Bachelor of Mathematics at the Ecole Normale Supérieure and an MSc in Theoretical Probability. After his PhD in Applied Mathematics and Computational Biology at the University of Southern California, he moved to the Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory at the University of Cambridge in 2006 to study the genetics of autoimmune disorders, in particular type 1 diabetes. Following this postdoc in Cambridge, he became a Lecturer (2009), and then a Reader (2013), in Statistical Genetics at the University College London (UCL) Genetics Institute (UGI). At the UGI he leads a computational research group working at the intersection between statistics, computer science and genetics, with a focus on translational research, in particular rare disease genetics and non-invasive prenatal diagnostics based on cell-free fetal DNA.